DE2929596A1 - Verfahren zur herstellung von oxoalkyl-xanthinen - Google Patents
Verfahren zur herstellung von oxoalkyl-xanthinenInfo
- Publication number
- DE2929596A1 DE2929596A1 DE19792929596 DE2929596A DE2929596A1 DE 2929596 A1 DE2929596 A1 DE 2929596A1 DE 19792929596 DE19792929596 DE 19792929596 DE 2929596 A DE2929596 A DE 2929596A DE 2929596 A1 DE2929596 A1 DE 2929596A1
- Authority
- DE
- Germany
- Prior art keywords
- xanthines
- oxoalkyl
- alkyl
- radical
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims description 16
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- -1 5-Oxohexyl Chemical group 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XBWPXAGHBDBODX-UHFFFAOYSA-N 8-(5-oxohexyl)-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(CCCCC(=O)C)N2 XBWPXAGHBDBODX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- CNAULKGFZUMSBZ-UHFFFAOYSA-N 5-oxohexyl 4-methylbenzenesulfonate Chemical compound CC(=O)CCCCOS(=O)(=O)C1=CC=C(C)C=C1 CNAULKGFZUMSBZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- UALYCKSVHDYQRP-UHFFFAOYSA-N 6-hydroxyhexan-2-one Chemical compound CC(=O)CCCCO UALYCKSVHDYQRP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- XBEDAMVJWVPVDS-UHFFFAOYSA-N 1,3-dimethyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCCC(=O)C XBEDAMVJWVPVDS-UHFFFAOYSA-N 0.000 description 1
- YOTSOUGNZSULJR-UHFFFAOYSA-N 1-hexyl-3-methyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(CCCCC(C)=O)C=N2 YOTSOUGNZSULJR-UHFFFAOYSA-N 0.000 description 1
- YQVZYDGEMBFDCB-UHFFFAOYSA-N 3-butyl-1-methyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(CCCC)C2=C1N(CCCCC(C)=O)C=N2 YQVZYDGEMBFDCB-UHFFFAOYSA-N 0.000 description 1
- MHNVSFOURBQRPK-UHFFFAOYSA-N 3-methyl-7-propylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2CCC MHNVSFOURBQRPK-UHFFFAOYSA-N 0.000 description 1
- QVMZOLZGAZBZJS-UHFFFAOYSA-N 5-oxohexyl methanesulfonate Chemical compound CC(=O)CCCCOS(C)(=O)=O QVMZOLZGAZBZJS-UHFFFAOYSA-N 0.000 description 1
- SOCYNBJTSAFFQI-UHFFFAOYSA-N 7-butyl-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCCC SOCYNBJTSAFFQI-UHFFFAOYSA-N 0.000 description 1
- SAEKTFXZAVNNEC-UHFFFAOYSA-N 7-hexyl-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCCCCC SAEKTFXZAVNNEC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000572 bronchospasmolytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792929596 DE2929596A1 (de) | 1979-07-21 | 1979-07-21 | Verfahren zur herstellung von oxoalkyl-xanthinen |
| GR62506A GR69741B (https=) | 1979-07-21 | 1980-01-28 | |
| ES493385A ES8105005A1 (es) | 1979-07-21 | 1980-07-15 | Procedimiento para la preparacion de oxoalcohil-xantinas |
| FI802267A FI802267A7 (fi) | 1979-07-21 | 1980-07-17 | Menetelmä oksoalkyyli-ksantiinien valmistamiseksi. |
| EP80104171A EP0023032A1 (de) | 1979-07-21 | 1980-07-17 | Verfahren zur Herstellung von Oxoalkyl-xanthinen |
| DK311580A DK311580A (da) | 1979-07-21 | 1980-07-18 | Fremgangsmaade til fremstilling af oxoalkylxanthiner |
| AR281813A AR227645A1 (es) | 1979-07-21 | 1980-07-18 | Procedimiento para la preparacion de oxoalcohilxantinas |
| NO802173A NO802173L (no) | 1979-07-21 | 1980-07-18 | Fremgangsmaate til fremstilling av oksoalkyl-xantiner |
| JP9883880A JPS5616486A (en) | 1979-07-21 | 1980-07-21 | Manufacture of oxoalkylxanthine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792929596 DE2929596A1 (de) | 1979-07-21 | 1979-07-21 | Verfahren zur herstellung von oxoalkyl-xanthinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2929596A1 true DE2929596A1 (de) | 1981-02-05 |
Family
ID=6076378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792929596 Withdrawn DE2929596A1 (de) | 1979-07-21 | 1979-07-21 | Verfahren zur herstellung von oxoalkyl-xanthinen |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0023032A1 (https=) |
| JP (1) | JPS5616486A (https=) |
| AR (1) | AR227645A1 (https=) |
| DE (1) | DE2929596A1 (https=) |
| DK (1) | DK311580A (https=) |
| ES (1) | ES8105005A1 (https=) |
| FI (1) | FI802267A7 (https=) |
| GR (1) | GR69741B (https=) |
| NO (1) | NO802173L (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0157098A1 (en) * | 1980-06-21 | 1985-10-09 | Beecham Wuelfing GmbH & Co KG | Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation |
| GB8418430D0 (en) * | 1984-07-19 | 1984-08-22 | Beecham Wuelfing Gmbh & Co Kg | Treatment |
| GB8501488D0 (en) * | 1985-01-21 | 1985-02-20 | Beecham Group Plc | Treatment |
| US4851060A (en) * | 1987-08-12 | 1989-07-25 | Essex Group, Inc. | Multilayer wrapped insulated magnet wire |
| CA2030112A1 (en) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same |
| DE3942872A1 (de) * | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2336403A1 (fr) * | 1975-12-24 | 1977-07-22 | Bruneau & Cie Lab | Nouveau procede de preparation de l'acide (theophyllinyl-7)-3 propanesulfonique |
| GB1527543A (en) * | 1976-04-15 | 1978-10-04 | Degussa | Basically substituted xanthine derivatives |
| DE2714953C2 (de) * | 1977-04-02 | 1986-09-25 | Hoechst Ag, 6230 Frankfurt | Arzneimittel |
-
1979
- 1979-07-21 DE DE19792929596 patent/DE2929596A1/de not_active Withdrawn
-
1980
- 1980-01-28 GR GR62506A patent/GR69741B/el unknown
- 1980-07-15 ES ES493385A patent/ES8105005A1/es not_active Expired
- 1980-07-17 EP EP80104171A patent/EP0023032A1/de not_active Withdrawn
- 1980-07-17 FI FI802267A patent/FI802267A7/fi not_active Application Discontinuation
- 1980-07-18 NO NO802173A patent/NO802173L/no unknown
- 1980-07-18 AR AR281813A patent/AR227645A1/es active
- 1980-07-18 DK DK311580A patent/DK311580A/da unknown
- 1980-07-21 JP JP9883880A patent/JPS5616486A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GR69741B (https=) | 1982-07-12 |
| FI802267A7 (fi) | 1981-01-01 |
| EP0023032A1 (de) | 1981-01-28 |
| ES493385A0 (es) | 1981-05-16 |
| ES8105005A1 (es) | 1981-05-16 |
| AR227645A1 (es) | 1982-11-30 |
| DK311580A (da) | 1981-01-22 |
| JPS5616486A (en) | 1981-02-17 |
| NO802173L (no) | 1981-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2929596A1 (de) | Verfahren zur herstellung von oxoalkyl-xanthinen | |
| EP0071738B1 (de) | Neue Theophyllinderivate und Verfahren zu deren Herstellung | |
| DE1620694C3 (de) | Verfahren zur Herstellung von 5-Methyl-7-diäthylamino-s-triazolo [1,5-a] pyrimidin und seinen Salzen mit Säuren | |
| CH634567A5 (de) | Verfahren zur herstellung von uracilderivaten. | |
| DE1645903C3 (de) | Verfahren zur Herstellung von 3 Halogen-3H-1,2-dihydro-1,4-benzodiazepin-2-on-derivaten | |
| DE2726754A1 (de) | Substituierte (3-niedrigalkylamino- 2-acyl-0-propoxy)-pyridine, verfahren zu ihrer herstellung und ihre verwendung | |
| DE2819886C2 (https=) | ||
| CH659464A5 (de) | Verfahren zur herstellung von 1,8-dihydroxy-10-acyl-9-anthronen. | |
| CH642365A5 (de) | Verfahren zur herstellung von 6-piperidino-2,4-diaminopyrimidin-3-oxid. | |
| CH628336A5 (de) | Verfahren zur herstellung von 5-fluoruracil und dessen derivaten. | |
| DE812316C (de) | Verfahren zur Herstellung von 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidin | |
| EP0001760B1 (de) | Alpha-aminomethylen-beta-formylaminopropionitril, Verfahren zu seiner Herstellung sowie Verwendung zur Herstellung von 2-Methyl-4-amino-5-formylaminomethyl-pyrimidin | |
| DE602004000253T2 (de) | Verfahren zur Herstellung von Hexahydropyridazin-3-carbonsäure-Derivaten | |
| DE2521347B2 (de) | Hydroxylsubstituierte 2-Chlor- a -(tertbutylaminomethyD-benzylalkohole, Herstellungsverfahren und Arzneimittel | |
| EP0552759A1 (de) | Verfahren zur Herstellung von 4,6-Dialkoxypyrimidinen | |
| DE2033090C3 (de) | deren Herstellung | |
| DE2637665A1 (de) | 5-substituierte 5h-dibenz(b,f)azepin- derivate und verfahren zu deren herstellung | |
| EP0582288A1 (de) | Verfahren zur Herstellung von 2-Halogen-4,6-dialkoxypyrimidinen | |
| EP0006451A1 (de) | Neue Imidazo(1,2-a)imidazole, deren Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung | |
| DE2657709A1 (de) | Verfahren zur herstellung von n hoch 1 -(2-tetrahydrofuryl)-5- fluoruracil | |
| EP0175264B1 (de) | Verfahren zur Herstellung von 2-Amino-3-cyano-5-dialkoxymethyl-pyrazinen und Zwischenprodukte für dieses Verfahren | |
| DE69124241T2 (de) | Verfahren zur herstellung von sulfonylpristinamycin iib | |
| EP0684243A1 (de) | Verfahren zur Herstellung von 2-Amino-6-chlorpurin und 2-Acylamino-6-chlorpurinen | |
| CH667093A5 (de) | Verfahren zur herstellung des aethylesters der apovincamin-saeure. | |
| DE952715C (de) | Verfahren zur Herstellung neuer antihistaminwirksamer basischer AEther |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8130 | Withdrawal |